The Technical Analyst
Panacea Acquisition Corp. [NUVB]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Panacea Acquisition Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.95% $3.32
America/New_York / 9 mai 2024 @ 14:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 722.82 mill |
| EPS: | -0.350 |
| P/E: | -9.47 |
| Earnings Date: | Jun 03, 2024 |
| SharesOutstanding: | 218.05 mill |
| Avg Daily Volume: | 1.470 mill |
| RATING 2024-05-09 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.47 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.23x |
| Company: PE -9.47 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.177 (-94.67%) $-3.14 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.02 - 3.60 ( +/- 8.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Cui Xiangmin | Buy | 4 183 002 | Class A Common Stock |
| 2024-04-09 | Cui Xiangmin | Buy | 1 675 236 | Class A Common Stock |
| 2024-04-09 | Cui Xiangmin | Buy | 314 106 | Class A Common Stock |
| 2024-04-09 | Cui Xiangmin | Buy | 0 | |
| 2024-04-09 | Sjogren Colleen | Buy | 500 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 94.06 |
| Last 97 transactions |
| Buy: 43 735 081 | Sell: 11 578 450 |
Forecast:
15:48 - $3.31
Live Trading Signals (every 1 min)
Forecast
1: 14:18 - $3.31
Forecast 2: 15:08 - $3.32
Forecast 3: 15:48 - $3.31
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.32 (2.95% ) |
| Volume | 0.442 mill |
| Avg. Vol. | 1.470 mill |
| % of Avg. Vol | 30.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NUVB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Latest Press Releases
2024-04-24 10:01:00 - Press Release
Nuvation Bio To Present Updated Data On Taletrectinib, A Ros1 Inhibitor, At The 2024 American Society Of Clinical Oncology (asco) Annual Meeting
New york--(business wire)--nuvation bio inc. (nyse: nuvb), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the phase 2 trust-i clinical study (nct04395677) evaluating taletrectinib in patients in china with ros1-positive non-small cell lung cancer (nsclc) will be reported in an oral presentation at the 2024 american society of clinical oncolo.
2024-04-10 16:01:00 - Press Release
Nuvation Bio Completes Acquisition Of Anheart Therapeutics
New york--(business wire)--nuvation bio inc. (nyse: nuvb), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of anheart therapeutics ltd. (anheart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. with the acquisition's completion, anheart is now a wholly-owned subsidiary of.
2024-03-28 08:00:00 - Press Release
Nuvation Bio Announces Appointment Of Colleen Sjogren As Chief Commercial Officer
New york--(business wire)--nuvation bio inc. (nyse: nuvb), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of colleen sjogren as chief commercial officer. ms. sjogren will lead the company's commercial strategy and operations, including marketing, sales, and market access. “we are thrilled to welcome colleen as nuvation bio's first chief commercial officer. she is an.
2024-03-25 07:00:00 - Press Release
Nuvation Bio To Acquire Anheart Therapeutics In All-stock Transaction
New york--(business wire)--nuvation bio inc. (nyse: nuvb), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and anheart therapeutics ltd. (anheart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced that the companies have entered into a definitive agreement for nuvation bio to acquire anheart in an all-stock transaction (th.
2024-03-14 16:05:00 - Press Release
Nuvation Bio Doses First Patient In Phase 1/2 Study Of Nuv-1511 For The Treatment Of Advanced Solid Tumors
New york--(business wire)--nuvation bio inc. (nyse: nuvb), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a phase 1/2 study of nuv-1511, the company's first ddc to enter the clinic. “dosing the first patient with nuv-1511 marks a significant milestone for our proprietary ddc platform, from which we are developing potent oncology-focused chime.
Latest News
2024-04-24 10:01:00 - Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncolo.
2024-03-31 10:00:00 - Seeking Alpha
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help.
2024-03-08 13:01:19 - Zacks Investment Research
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-03-18 18:48:06 - InvestorPlace
The 7 Worst Stocks to Buy Now
Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.
2022-06-27 09:08:02 - Benzinga
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a.
2022-01-21 11:35:10 - Zacks Investment Research
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
2022-01-20 08:43:59 - Benzinga
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and differentiation.
2021-12-13 12:01:57 - Benzinga
Why Nuvation Bio Shares Are Rising
Nuvation Bio Inc (NYSE:NUVB) shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422. "FDA clearance of our third IND application for NUV-422 is another important achievement for our lead investigational CDK 2/4/6 inhibitor program as we develop our deep pipeline of innovative new cancer therapeutics across a variety of tumor types," said David Hung, M.D.
2021-06-01 07:00:00 - PRNewsWire
Nuvation Bio Appoints David C. Hanley, Ph.D.
NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D.
2021-05-26 07:00:00 - PRNewsWire
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
NEW YORK, May 26, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that David Hung, M.D., founder and chief executive officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 9:00 a.m.